Our resources are free to access. Log in and record your professional development using our CAPTURE function (at the bottom of each article).
At He Ako Hiringa our mission is to contribute to eliminating inequitable access to funded medicines.
Prescribers wanting to block angiotensin II effects can consider the remaining funded ACE inhibitors or angiotensin II receptor blockers. ACE inhibitors and ARBs are similarly effective for hypertension, chronic renal disease and diabetic nephropathy, but ARBs are better tolerated.2 ACE inhibitors are preferred over ARBs first-line for heart failure and post myocardial infarction.2
Read the HAH Bulletin to find out more.
Dulaglutide, a once-weekly injectable medicine, will soon be available for second-line treatment of type 2 diabetes. As most people with type 2 diabetes will require an injectable therapy at some stage, it is important to build acceptability early in the patient journey.
Careful writing and editing, and an equity lens, have been instrumental in updating the type 2 diabetes HealthPathways, helping to reduce unnecessary variation in treatment plans and outcomes.
When clinically indicated, empagliflozin can be started in adult patients with type 2 diabetes using the steps shown in this resource.
Talking points, relevant for all patients starting empagliflozin, are provided along with two algorithms and accompanying prescribing notes. Which algorithm you follow will depend on your patient’s level of hypoglycaemia risk.
Focusing on the experiences of older Māori in primary care, this course comprises four short videos, an independent reflection, downloadable posters and additional resources.
The course is endorsed by RNZCGP and CNA(NZ) and meets PCNZ recertification requirements. Reflection templates are included for you to complete.
This Quality Improvement Activity enables you to review the glycaemic management of your type 2 diabetes patients and identify those who may benefit from initiation or intensification of blood glucose lowering medicines.
Good glycaemic control has a clear benefit on microvascular outcomes and if started early enough, on long-term macrovascular outcomes of coronary artery disease, stroke and peripheral vascular disease.
This is a Measuring and Improving Outcomes (MIO) activity that meets RNZCGP CPD requirements.
Subscribe to our newsletter to remain up to date with all our content and new features.